Beam Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Beam Therapeutics Inc. (BEAM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.27 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-04
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 482.41K shares, a 29.84% increase year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 1.79M shares, a 17.12% decline year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 50.90K shares, a 78.96% decline year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 145.35K shares, a 17.26% decline year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.72M shares, a 1.69% increase from fiscal 2024.
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.68M shares, a 13.63% increase from fiscal 2023.
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 2.36M shares, a 6.39% increase from fiscal 2022.
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.22M shares, a 23.72% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 482.41K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 2.27M shares 10-Q · filed 2026-08-04 | 2.32M shares derived: sum of 3 quarters · filed 2026-08-04 | 2.47M shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 1.79M shares 10-Q · filed 2026-05-07 | 1.84M shares derived: sum of 2 quarters · filed 2026-05-07 | 1.98M shares derived: sum of 3 quarters · filed 2026-05-07 | 2.35M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 50.90K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | 196.25K shares derived: sum of 2 quarters · filed 2026-02-24 | 567.78K shares derived: sum of 3 quarters · filed 2026-02-24 | 2.72M shares 10-K · filed 2026-02-24 |
| 2025-09-30 | 145.35K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 516.88K shares derived: sum of 2 quarters · filed 2025-11-04 | 2.67M shares 10-Q · filed 2025-11-04 | 2.91M shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 371.53K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 2.53M shares 10-Q · filed 2025-08-05 | 2.77M shares derived: sum of 3 quarters · filed 2025-08-05 | 2.94M shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 2.16M shares 10-Q · filed 2025-05-06 | 2.40M shares derived: sum of 2 quarters · filed 2025-05-06 | 2.57M shares derived: sum of 3 quarters · filed 2025-05-06 | 2.89M shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 241.89K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | 417.56K shares derived: sum of 2 quarters · filed 2025-02-25 | 730.85K shares derived: sum of 3 quarters · filed 2025-02-25 | 2.68M shares 10-K · filed 2025-02-25 |
| 2024-09-30 | 175.68K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | 488.96K shares derived: sum of 2 quarters · filed 2024-11-05 | 2.44M shares 10-Q · filed 2024-11-05 | 2.55M shares derived: sum of 4 quarters · filed 2024-11-05 |
| 2024-06-30 | 313.28K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 2.26M shares 10-Q · filed 2024-08-06 | 2.37M shares derived: sum of 3 quarters · filed 2024-08-06 | 2.58M shares derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | 1.95M shares 10-Q · filed 2024-05-07 | 2.06M shares derived: sum of 2 quarters · filed 2024-05-07 | 2.27M shares derived: sum of 3 quarters · filed 2024-05-07 | 2.53M shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | 111.45K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 323.20K shares derived: sum of 2 quarters · filed 2024-02-27 | 586.49K shares derived: sum of 3 quarters · filed 2024-02-27 | 2.36M shares 10-K · filed 2024-02-27 |
| 2023-09-30 | 211.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 475.04K shares derived: sum of 2 quarters · filed 2023-11-08 | 2.25M shares 10-Q · filed 2023-11-08 | 2.41M shares derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-06-30 | 263.29K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 2.03M shares 10-Q · filed 2023-08-08 | 2.20M shares derived: sum of 3 quarters · filed 2023-08-08 | 2.49M shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 1.77M shares 10-Q · filed 2023-05-10 | 1.93M shares derived: sum of 2 quarters · filed 2023-05-10 | 2.23M shares derived: sum of 3 quarters · filed 2023-05-10 | 2.56M shares derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | 163.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 460.15K shares derived: sum of 2 quarters · filed 2023-02-28 | 787.75K shares derived: sum of 3 quarters · filed 2023-02-28 | 2.22M shares 10-K · filed 2023-02-28 |
| 2022-09-30 | 296.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | 624.35K shares derived: sum of 2 quarters · filed 2022-11-07 | 2.05M shares 10-Q · filed 2022-11-07 | 2.20M shares derived: sum of 4 quarters · filed 2022-11-07 |
| 2022-06-30 | 327.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 1.76M shares 10-Q · filed 2022-08-09 | 1.91M shares derived: sum of 3 quarters · filed 2022-08-09 | 2.31M shares derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | 1.43M shares 10-Q · filed 2022-05-09 | 1.58M shares derived: sum of 2 quarters · filed 2022-05-09 | 1.98M shares derived: sum of 3 quarters · filed 2022-05-09 | 2.23M shares derived: sum of 4 quarters · filed 2022-05-09 |
| 2021-12-31 | 152.33K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | 553.93K shares derived: sum of 2 quarters · filed 2022-02-28 | 797.82K shares derived: sum of 3 quarters · filed 2022-02-28 | 1.79M shares 10-K · filed 2022-02-28 |
| 2021-09-30 | 401.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | 645.48K shares derived: sum of 2 quarters · filed 2021-11-08 | 1.64M shares 10-Q · filed 2021-11-08 | 1.78M shares derived: sum of 4 quarters · filed 2021-11-08 |
| 2021-06-30 | 243.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | 1.24M shares 10-Q · filed 2021-08-10 | 1.38M shares derived: sum of 3 quarters · filed 2021-08-10 | 1.60M shares derived: sum of 4 quarters · filed 2021-08-10 |
| 2021-03-31 | 992.66K shares 10-Q · filed 2021-05-11 | 1.13M shares derived: sum of 2 quarters · filed 2021-05-11 | 1.36M shares derived: sum of 3 quarters · filed 2021-05-11 | 1.53M shares derived: sum of 4 quarters · filed 2021-05-11 |
| 2020-12-31 | 140.95K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | 367.65K shares derived: sum of 2 quarters · filed 2021-03-15 | 537.46K shares derived: sum of 3 quarters · filed 2021-03-15 | 1.49M shares 10-K · filed 2021-03-15 |
| 2020-09-30 | 226.70K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | 396.51K shares derived: sum of 2 quarters · filed 2020-11-10 | 1.35M shares 10-Q · filed 2020-11-10 | |
| 2020-06-30 | 169.81K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | 1.12M shares 10-Q · filed 2020-08-12 | ||
| 2020-03-31 | 949.64K shares 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |